Relypsa Obtains $70,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    5301 Patrick Henry Drive Santa Clara, CA 95054
  • Company Description
    Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will support the advancement of Relypsa’s lead compound, RLY5016, through pivotal clinical studies.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
  • Venture Investor
    Delphi Ventures

Trending on Xconomy